Researchers Discover Mutations Behind Resistance to PARP Inhibitors Like Lynparza

Researchers Discover Mutations Behind Resistance to PARP Inhibitors Like Lynparza
Scientists have found mutations in the poly ADP-ribose polymerase (PARP) gene that cause resistance to PARP inhibitor therapies — such as Lynparza (olaparib) — in a mouse model and in one patient with ovarian cancer, according to a recent study. Detection of these mutations could help physicians to predict which cancer patients are likely to develop

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *